Patent Challenges Via IPR Still Pretty Scary, Even After Acorda's Win

Reform efforts gain steam, but hedge fund manager Kyle Bass' attack on Acorda's patents was denied based on specifics of prior art, not biotech's arguments about abuse of the system.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America